Experts Debated Complement Inhibitors for Eye Disease

Ophthalmologists voiced skepticism regarding the clinical value of new treatments for geographic atrophy during an annual meeting.

Updated on Oct. 12, 2026 in Alzheimer’s

Experts Debated Complement Inhibitors for Eye Disease

Live Poll

Do you believe medical treatments are worth potential side effects over lifestyle-based alternatives?

Experts gathered at the 2026 American Academy of Ophthalmology annual meeting to debate the efficacy and safety of complement inhibitors for treating geographic atrophy. A session poll revealed significant audience skepticism regarding the clinical benefits of these medications.

Why it matters

The debate sought to address the clinical value and associated risks of these treatments, as many in the medical community remain unconvinced they meaningfully alter patient outcomes. This highlights an ongoing struggle to reconcile clinical trial results with real-world physician practices.

Clinical trials show complement inhibitors reduce geographic atrophy progression by 21%, while the AREDS1 and AREDS2 studies demonstrated progression reductions of 36% and 35% respectively. Adverse event reporting indicates vasculitis occurs in 1 in 4,000 injections.

The players

American Academy of Ophthalmology

This is the world's largest association of eye physicians and surgeons which facilitates research and professional development for the field.

The details

Complement inhibitors like pegcetacoplan and avacincaptad pegol require monthly injections, creating a burden for patients and providers. Physicians at the session used an applause-based vote to signify their hesitation to adopt these therapies widely in their practice.

The debate occurred during the American Academy of Ophthalmology annual meeting in October 2026.

Health Landscape

The debate over complement inhibitors follows the historical success of the Age-Related Eye Disease Study (AREDS), which established long-standing benchmarks for slowing disease progression. This signals a shifting landscape as practitioners weigh newer pharmacological interventions against proven, established dietary and supplement protocols.

Patients currently undergoing or considering treatment for geographic atrophy should discuss these findings with their ophthalmologist to weigh the potential 21% progression reduction against the risk of rare but serious complications like vasculitis. The ongoing uncertainty among many physicians suggests that individual care plans should be tailored to address specific patient risk factors and expectations.

The takeaway

Clinicians are increasingly critical of the real-world utility of new geographic atrophy treatments despite positive trial results. Patients should prioritize clear communication with their doctors regarding the risks of frequent injections and whether these therapies offer clear benefits for their unique case.